Ken Griffin Genenta Science S.P.A. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Genenta Science S.P.A. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,486 shares of GNTA stock, worth $27,469. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,486Holding current value
$27,469% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding GNTA
# of Institutions
7Shares Held
552KCall Options Held
0Put Options Held
0-
Allianz Se Munich, 2M234KShares$514,9100.02% of portfolio
-
Al Ti Global, Inc. New York, NY200KShares$440,6330.01% of portfolio
-
Algebris (Uk) LTD London, X0100KShares$220,0000.04% of portfolio
-
National Bank Of Canada3KShares$6,6000.0% of portfolio
-
Morgan Stanley New York, NY2.2KShares$4,8400.0% of portfolio
About Genenta Science S.p.A.
- Ticker GNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,216,900
- Market Cap $40.1M
- Description
- Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated...